An Open-Label Pilot Study of the Pharmacokinetics and Safety of 50 Mg Oral Testosterone Undecanoate (Kyzatrex) in Menopausal Women With Low Testosterone and Hypoactive Sexual Desire Disorder
Latest Information Update: 18 Nov 2024
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Female sexual dysfunction
- Focus Pharmacokinetics
Most Recent Events
- 13 Nov 2024 Planned End Date changed from 1 Dec 2025 to 31 Dec 2025.
- 13 Nov 2024 Planned primary completion date changed from 1 Jun 2025 to 31 Dec 2025.
- 13 Nov 2024 Planned initiation date changed from 1 Dec 2023 to 1 Jan 2025.